ID   FP0-AgR-neo
AC   CVCL_E2UD
RX   Patent=US8859278;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7466.
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Transformant: NCIt; C17231; Ultraviolet radiation.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C9357; Hodgkin lymphoma
DI   ORDO; Orphanet_98293; Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_E2UC ! FP0-AgR
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   Patent=US8859278;
RA   Trakht I., Kalantarov G.F.;
RT   "Fully human hybridoma fusion partner cell lines.";
RL   Patent number US8859278, 14-Oct-2014.
//